GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bionik Laboratories Corp (OTCPK:BNKL) » Definitions » Gross Profit

Bionik Laboratories (Bionik Laboratories) Gross Profit : $0.99 Mil (TTM As of Mar. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Bionik Laboratories Gross Profit?

Bionik Laboratories's gross profit for the three months ended in Mar. 2023 was $0.25 Mil. Bionik Laboratories's gross profit for the trailing twelve months (TTM) ended in Mar. 2023 was $0.99 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Bionik Laboratories's gross profit for the three months ended in Mar. 2023 was $0.25 Mil. Bionik Laboratories's Revenue for the three months ended in Mar. 2023 was $0.50 Mil. Therefore, Bionik Laboratories's Gross Margin % for the quarter that ended in Mar. 2023 was 50.70%.

Bionik Laboratories had a gross margin of 50.70% for the quarter that ended in Mar. 2023 => Durable competitive advantage


Bionik Laboratories Gross Profit Historical Data

The historical data trend for Bionik Laboratories's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionik Laboratories Gross Profit Chart

Bionik Laboratories Annual Data
Trend Dec14 Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.62 1.26 0.92 0.95 0.99

Bionik Laboratories Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.17 0.30 0.27 0.25

Competitive Comparison of Bionik Laboratories's Gross Profit

For the Medical Care Facilities subindustry, Bionik Laboratories's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionik Laboratories's Gross Profit Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Bionik Laboratories's Gross Profit distribution charts can be found below:

* The bar in red indicates where Bionik Laboratories's Gross Profit falls into.



Bionik Laboratories Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Bionik Laboratories's Gross Profit for the fiscal year that ended in Mar. 2023 is calculated as

Gross Profit (A: Mar. 2023 )=Revenue - Cost of Goods Sold
=1.805 - 0.815
=0.99

Bionik Laboratories's Gross Profit for the quarter that ended in Mar. 2023 is calculated as

Gross Profit (Q: Mar. 2023 )=Revenue - Cost of Goods Sold
=0.501 - 0.247
=0.25

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.99 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Bionik Laboratories's Gross Margin % for the quarter that ended in Mar. 2023 is calculated as

Gross Margin % (Q: Mar. 2023 )=Gross Profit (Q: Mar. 2023 ) / Revenue (Q: Mar. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.25 / 0.501
=50.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Bionik Laboratories  (OTCPK:BNKL) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Bionik Laboratories had a gross margin of 50.70% for the quarter that ended in Mar. 2023 => Durable competitive advantage


Bionik Laboratories Gross Profit Related Terms

Thank you for viewing the detailed overview of Bionik Laboratories's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionik Laboratories (Bionik Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
80 Coolidge Hill Road, Watertown, MA, USA, 02472
Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and innovative robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.
Executives
Remi Gaston-dreyfus director, 10 percent owner 46 RUE PIERRE CHARRON, PARIS I0 75008
Charles Matine director 7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017
Andre-jacques Auberton-herve director, officer: Chairman 18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700
Daniel Gonsalves officer: Executive Vice President & CFO 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Loren W. Wass officer: See Remarks 34 HOG HILL ROAD, PEPPERELL MA 01463
Joseph R Martin director
Audrey Thevenon director 4500 WESTBROOK LANE, KENSINGTON MD 20895
Peter Gerald Malone director
Russo Richard Paul Jr officer: Chief Financial Officer 20 PLUNKETT WAY, TEWKSBURY MA 01876
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
Timothy A. Mccarthy officer: Chief Commercialization Office C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9
Eric Michel Dusseux director 1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300
Jules Marc Fried officer: VP - U.S. Operations C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Hermano Igo Krebs officer: Chief Science Officer C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Marc Mathieu director 716 BROOKS AVENUE, VENICE CA 90291